Clinical management of hypertension associated with high cardiovascular risk


Hypertension is a common disease, which is highly prevalent in the general population (occurring in around 20–30% of adults). The clinical approach to hypertensive disease should not be limited to just normalization of blood pressure values, but should also include an assessment of global cardiovascular risk. Guidelines make very clear that the risk for patients with hypertensive is not limited to their blood pressure values, but also depends on the concomitant presence of other cardiovascular risk factors, cardiac, vascular or renal organ damage and associated disease(s), including coronary artery disease or heart failure. Through an illustrative, interactive clinical case presentation, Professor Tadic will discuss in detail and in context, the relationship between hypertension and cardiovascular risk, including the basic diagnostic steps that are needed for the correct clinical approach and the choice of therapeutic options for patients.


By attending this online interactive activity, learners will be able to:

  1. Acquire information about the relationship between blood pressure values and global cardiovascular risk
  2. Examine the best clinical approach to identify the main conditions associated with increased cardiovascular risk in hypertensive patients
  3. Discuss the best therapeutic approaches for hypertensive patients based on their risk profiles
  4. Define the best pharmacological options for patients with very high cardiovascular risk including hypertensive patients with coronary artery disease or heart failure


This activity is designed for Cardiologists, General Practitioners, Internists and those treating patients with cardiovascular disorders.


Marijana Tadic
Honorary consultant
University Hospital “Dr. Dragisa Misovic”
Belgrade, Serbia



Marijana Tadic, MD, PhD is a specialist and Associate Professor in Internal Medicine and Cardiology. She was trained in Serbia, Italy, UK, Netherlands and Germany. Her main interest is diagnosis of cardiac remodeling in broad spectrum of cardiovascular diseases and particularly in arterial hypertension. She has a large experience in multimodality cardiac imaging in patients with hypertension, diabetes, obesity and metabolic syndrome. She is also interested the clinical pharmacology of cardiovascular drugs. Dr. Tadic is the author of more than 300 research articles, editorial member of several large cardiology journals and received several important grants including those from European Society of Cardiology.


Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Marijana Tadic                      Declared no potential conflict of interest


All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.


This activity will be in English.


30 June 2021


To access the resource online, click here and login:

For information about the program, please contact:
Scientific Seminars International Foundation
T +39 380 1504116 – F +39 06 4827169


This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.

Copyright 2021 Scientific Seminars International Foundation